" We have had a graveyard of clinical trials, due to the wrong target, the compound not doing what we thought it would do, the wrong measures, etfc. But it was also because of a not-optimal selection of participants in our trials. If we keep trying to intervene late, we are hoping for a drug we just won’t have. It may be easier to slow the disease down before it’s caused so much damage to the brain so we need to enroll people in clinical trials earlier and if we do that we have to make sure they’re high risk and on the path to the disease. Early screening that is reliable is something we have to have in order to later develop therapeutics that stand a hope of slowing this down. "